Last update:
Clinical pharmacology news
How do GLP-1 agonists affect gene expression?
GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health. ...
12 hours ago
0
0
PET imaging study reveals how ketamine relieves treatment-resistant depression
Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional ...
14 hours ago
0
0
Temporal lobe epilepsy: A new strategy to correct abnormal electrical activity
Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are eligible for the procedure. ...
14 hours ago
0
0
Smart combinations of antibiotics can slow down resistance
When a bacterium becomes resistant to one antibiotic, it may sometimes become more sensitive to another. This biological side-effect offers an unexpected opportunity in the fight against antibiotic resistance.
16 hours ago
0
0
Creating less trippy, more therapeutic 'magic mushrooms'
Psilocybin—the psychoactive compound in "magic mushrooms"—is gaining scientific attention for its potential in treating neuropsychiatric conditions including depression, anxiety, substance use disorders and certain neurodegenerative ...
17 hours ago
0
0
White House autism briefing linked to swift shifts in prescribing patterns
A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed ...
18 hours ago
1
0
AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared ...
7 hours ago
0
0
Intracellular signaling proteins emerge as a key target in drug development
In a recently published review, a research team led by MedUni Vienna has highlighted a promising new approach to drug discovery. The focus is on the targeted modulation of certain intracellular signaling proteins as a strategy ...
11 hours ago
0
0
Spray-on 'immune-shield' coats transplant organs to curb rejection
A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without causing systemic side effects. A research team from Pohang University of Science and Technology (POSTECH) ...
12 hours ago
0
0
Anti-obesity treatment could cost as little as $3 per month: Study
A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low- and ...
22 hours ago
0
0
Short bowel syndrome has no drugs: A new compound could cut liver risk
When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue. Although lifesaving, the procedure—referred to as a radical small bowel resection—can lead to long-term ...
23 hours ago
0
0
Single saRNA shot helps with healing after a heart attack
For people who have survived a heart attack, the notion of one shot in the arm to help the heart heal, for weeks after, may seem far-fetched. But thanks to a team of researchers, including a Texas A&M University professor, ...
Mar 5, 2026
0
0
Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, ...
Mar 5, 2026
0
1
Combination therapy reduces effects of 'zombie cells' in diabetic kidney disease, research finds
Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells—also known as "zombie cells"—in diabetic kidney disease. In eBioMedicine, ...
Mar 5, 2026
0
0
Cannabis compounds show promise in fighting fatty liver disease
Researchers have discovered that non-psychoactive cannabis compounds, CBD and CBG, can significantly reduce liver fat and improve metabolic health. The study reveals that these compounds work by creating a backup energy reserve ...
Mar 5, 2026
0
2
What to know about how GLP-1 medications might fight addiction
The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders—and reduce the tragic outcomes they cause, a large new study finds.
Mar 5, 2026
0
0
Testosterone therapy could mean trouble for knee replacement patients, study warns
Testosterone therapy is booming in the U.S., but it might bring higher risks for people undergoing knee replacement surgery, a new study says.
Mar 5, 2026
0
0
GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people
A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. ...
Mar 5, 2026
0
0
GLP‑1 drugs like Ozempic may lower the risk of addiction: New study
A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study shows.
Mar 5, 2026
0
0
Dangerous health risks exposed in illicit steroid research program
Almost 90% of illegal steroids contain unexpected, incorrect or dangerous substances, a Queensland drug testing study has found. ROIDCheck—a project led by University of Queensland researchers—tested the purity of image ...
Mar 5, 2026
0
0
GLP-1 medications get at the heart of addiction, study finds
Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be effective at treating and preventing substance-use disorders across all major addictive substances ...
Mar 4, 2026
0
1
Psychedelics may aid PTSD recovery by repairing brain myelin, study finds
Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks. New research shows that treatment with psychedelic drugs triggers ...
Mar 4, 2026
0
0
First gene regulation clinical trials for epilepsy show promising results
A Phase I/IIa clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet ...
Mar 4, 2026
0
0
Common anticholinergic medicines may raise cardiovascular risk, large study suggests
People who use drugs with anticholinergic effects, including certain antidepressants, drugs for urinary incontinence and common antihistamines, are at higher risk of developing cardiovascular disease, according to a new study ...
Mar 4, 2026
0
1
No more weekly injections? How lettuce cells could deliver GLP-1 pills
Research led by Penn Dental's Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as a new oral delivery of two GLP-1 drugs previously approved by the FDA in injectable form.
Mar 4, 2026
0
2
Three distinct ADHD biotypes identified using a novel brain-first, data-driven approach
13 hours ago
13 hours ago
Wnt signaling drives stomach cancer spread by reshaping surrounding tissue, finds study
13 hours ago
13 hours ago
